R&D Programs archivos - Aptatargets

Post Title

LOREM IPSUM DOLOR SIT AMET

By Gemma Escarré R&D Programs

31 Jul: ApTOLL’s secondary analysis data of APRIL 1b/2a trial published in ‘Stroke’

LOREM IPSUM DOLOR SIT AMET

By Gemma Escarré R&D Programs

22 May: aptaTargets transferred ApTOLL to Merck

LOREM IPSUM DOLOR SIT AMET

By Gemma Escarré R&D Programs

23 Dec: aptaTargets awarded with the Programa Cheque Innovación 2024 from the Community of Madrid

LOREM IPSUM DOLOR SIT AMET

By Gemma Escarré R&D Programs

06 Jun: A new study shows the cerebroprotective effects of ApTOLL on mice with acute ischemic stroke

LOREM IPSUM DOLOR SIT AMET

By Gemma Escarré R&D Programs

20 May: Preclinical studies validate the potential of ApTOLL to reduce inflammation and regenerate myelin in models of multiple sclerosis

LOREM IPSUM DOLOR SIT AMET

By Gemma Escarré R&D Programs

06 May: aptaTargets CSO Macarena Hernández will speak at the 10th European Stroke Conference

LOREM IPSUM DOLOR SIT AMET

By Gemma Escarré R&D Programs

11 Mar: aptaTargets secures €2.5 million from the EU to initiate the Phase 2b clinical trial in patients with ischemic stroke

LOREM IPSUM DOLOR SIT AMET

By Gemma Escarré R&D Programs

19 Feb: aptaTargets receives a €1.9 million grant from the Community of Madrid

LOREM IPSUM DOLOR SIT AMET

By Gemma Escarré R&D Programs

22 Jan: aptaTargets receives €4 M for the Phase 2b clinical trial with ApTOLL in patients with ischemic stroke

LOREM IPSUM DOLOR SIT AMET

By Gemma Escarré R&D Programs

04 Oct: aptaTargets participates in a study with world leaders in stroke to improve enrollment in clinical trials

LOREM IPSUM DOLOR SIT AMET

1 2 … 5